IM Cannabis Corp. (NASDAQ:IMCC – Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 45,409 shares, a growth of 262.1% from the August 31st total of 12,539 shares. Based on an average trading volume of 76,668 shares, the days-to-cover ratio is currently 0.6 days. Currently, 23.3% of the shares of the company are sold short.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of IM Cannabis in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.
View Our Latest Stock Report on IMCC
IM Cannabis Price Performance
IM Cannabis (NASDAQ:IMCC – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter. IM Cannabis had a negative return on equity of 585.96% and a negative net margin of 39.62%.The business had revenue of $5.34 million for the quarter.
About IM Cannabis
IM Cannabis Corp. is a medical cannabis company that operates primarily in Israel and Germany. The company develops, imports, distributes and sells medical cannabis products through the IMC brand and related product lines.
Its product portfolio includes medical cannabis flower, oils and other cannabis-based products. In Israel, IM Cannabis serves the regulated medical cannabis market through activities that include product sourcing, distribution and sales to authorized patients and pharmacies.
Further Reading
- Five stocks we like better than IM Cannabis
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
